ATAI Life SciencesATAI
ATAI
About: ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.
Employees: 83
0
Funds holding %
of 6,809 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
70% more call options, than puts
Call options by funds: $134K | Put options by funds: $79K
0% more funds holding in top 10
Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]
1.88% less ownership
Funds ownership: 8.78% [Q2] → 6.9% (-1.88%) [Q3]
16% less funds holding
Funds holding: 88 [Q2] → 74 (-14) [Q3]
32% less capital invested
Capital invested by funds: $19.6M [Q2] → $13.4M (-$6.2M) [Q3]
48% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 23
67% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 21
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$10
713%
upside
Avg. target
$10.50
754%
upside
High target
$11
794%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Patrick Trucchio 30% 1-year accuracy 47 / 158 met price target | 713%upside $10 | Buy Maintained | 18 Nov 2024 |
Canaccord Genuity Sumant Kulkarni 25% 1-year accuracy 8 / 32 met price target | 794%upside $11 | Buy Maintained | 18 Nov 2024 |
Financial journalist opinion
Positive
Proactive Investors
1 month ago
atai Life Sciences shares set to be lifted by 2025 trial data readouts: analysts
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) shares should move higher on a slew of Phase 2 and 3 data readouts in 2025 from across its pipeline of innovative psychedelic therapies, analysts at Jefferies. Following the release of atai's third quarter results earlier this week, the analysts repeated their ‘Buy' rating on the stock and awarded it a $5 price target, implying upside of 242% from its share price at the time of writing.
Positive
Proactive Investors
1 month ago
atai Life Sciences advances therapeutic pipeline in Q3 with FDA approval of VLS-01
atai Life Sciences (NASDAQ:ATAI, ETR:9VC), a biopharmaceutical company targeting mental health disorders, advanced its pipeline of innovative therapies during the third quarter of 2024. Notably, the US Food and Drug Administration approved an investigational new drug application for for VLS-01, atai's buccal film formulation of DMT.
Positive
Proactive Investors
1 month ago
RFK Jr's appointment in health could accelerate psychedelic drug development, analysts say
President-elect Donald Trump's promise that Robert F Kennedy Junior (RFK Jr) will take on a “big role” in shaping health policy could be a positive for psychedelics given RKF Jr's well-documented support of this drug class, analysts at Jefferies believe. “RFK Jr seems positively inclined and sounds motivated to help foster psychedelic drug development,” analysts wrote in a note to clients, noting that psychedelics have reportedly helped his family and friends recover from trauma, severe depression and obsessive-compulsive disorder.
Neutral
GlobeNewsWire
2 months ago
IntelGenx is Granted Court Approval of the Sale Proposal from atai Life Sciences AG
MONTRÉAL, Oct. 02, 2024 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (the “Company” or “IntelGenx”), a leading drug delivery company focused on the development and manufacturing of pharmaceutical films, announces that the Company and its subsidiary IntelGenx Corp. (“IGX” and, together with the Company, the “IGX Entities”) have obtained on September 30, 2024 an approval and vesting order (the “Approval and Vesting Order”) from the Superior Court of Québec (Commercial Division) (the “Court”) issued in connection with the previously announced proceedings instituted pursuant to the Companies' Creditors Arrangement Act (the “CCAA”).
Neutral
GlobeNewsWire
3 months ago
atai Life Sciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
NEW YORK and BERLIN, Sept. 04, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the Company's management team is scheduled to participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York, NY from September 9-11, 2024. Details of the company's participation:
Positive
Seeking Alpha
3 months ago
Psychedelic Stock Deep Dive: Atai Life Sciences
After the FDA's rejection of Lykos Therapeutics' NDA for MDMA therapy, we take a more complete look at major psychedelic stocks. Atai Life Sciences is an early mover with a unique company structure and diverse pipeline that could minimize risk. Atai's stock is at historic lows, but with several upcoming Phase 2 milestones, a long-term position in ATAI could be a smart move.
Positive
Proactive Investors
4 months ago
atai Life Sciences chief scientific officer details VLS-01 trial success - ICYMI
atai Life Sciences (NASDAQ:ATAI, ETR:9VC)' chief scientific officer Dr Srinivas Rao joined Proactive to discuss the company's latest clinical trial results. Dr Rao detailed the positive outcomes from the Phase 1B trial of the VLS-01 (oral DMT) program, emphasizing the drug's excellent tolerability and potential as a best-in-class treatment option.
Positive
Proactive Investors
4 months ago
atai Life Sciences entering catalyst-rich period with key Phase2/3 trial data ahead
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has been awarded a 'Buy' rating from Jefferies analysts as the company's pipeline of mental health therapies enters a catalyst-rich period. “atai's pipeline of psychedelics (and non-psychedelics) has the potential to safely, profoundly, and durably treat tough $1 billion-plus in central nervous systems indications,” analysts wrote in a note to clients.
Positive
Proactive Investors
4 months ago
atai Life Sciences advances clinical pipeline in Q2, unveils positive VLS-01 trial results
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has provided an update on its research activities and told investors it has cash, marketable securities, and committed term loan funding available which is expected to fund its operations into 2026. In addition to announcing its second quarter financial results, atai on Tuesday unveiled positive preliminary Phase 1b trial results for VLS-01, its proprietary oral transmucosal film formulation of N,N-dimethyltryptamine (DMT) that is applied to the buccal surface.
Neutral
GlobeNewsWire
4 months ago
atai Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
• Reported positive Phase 1b results of VLS-01 (buccal film DMT); expect to initiate a Phase 2 study in treatment-resistant depression patients around YE'24 • Announced clinical development plans for EMP-01 (oral R-MDMA); expect to initiate a Phase 2 study of EMP-01 in social anxiety disorder patients around YE'24 • Cash, marketable securities, and committed term loan funding expected to fund operations into 2026 NEW YORK and BERLIN, Aug. 13, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced second quarter 2024 financial results and provided corporate updates. “Over the past quarter, we've made significant strides to advance our pipeline, with key updates from our VLS-01 and EMP-01 programs,” stated Dr. Srinivas Rao, Co-Chief Executive Officer and Co-founder of atai.
Charts implemented using Lightweight Charts™